Day(s)
:
Hour(s)
:
Minute(s)
:
Second(s)
OVERVIEW
As healthcare systems evolve, Pharmacoeconomics will remain a key discipline for guiding decisions that optimize outcomes, resource allocation, and the overall sustainability of healthcare.
The MEPDPS 2026: Middle East Pharmacoeconomics and Drug Policy Summit 2026 will take place on 18-19 April at Crowne Plaza RDC, Riyadh, KSA and has been meticulously crafted to serve as a dynamic platform for thought leaders, policymakers, and key stakeholders to exchange insights, share experiences, in the areas focused on healthcare policy, the HEOR in healthcare decision making, economic evaluations, VBHC, the implications of HTA, responses to Real-World Evidence, collaboration, affordability, and equity in healthcare, that enhance patient outcomes, ensure accessibility to innovative therapies, and contribute to the sustainability of our healthcare infrastructure.
Who Attended 2025 Summit
Conference Key Facts
WHO SHOULD ATTEND
- Regulatory authorities
- Pharmacoeconomists
- Health Economists
- Health Technology Assessment Specialists
- Payers
- Healthcare providers
- Pharma industry
- Pharmacists and more
KEY BENEFITS OF ATTENDING
- Highlight future opportunities and challenges in developing the healthcare and research economy in the GCC countries
- Discuss the novel approaches to value assessment, achieving cost effective healthcare solutions and access to innovative medicines in the GCC
- Understanding the principles of outcome based healthcare and evidence based medication
- Reviewing pharmacoeconomics and outcomes research strategies
- Exploring the real world data, the burden of disease and HTA to make proper assessments and support decision making
Summit chairman

Ahmed Al Jedai
SUMMIT VICE CHAIR

Mohammed Alshennawi
General Director, General Administration of Pharmaceutical Care, Ministry of Health, KSA
ORGANIZING COMMITTEE
CHAIR

Wejdan I. Aburas
Acting Director, Drug Policy and Regulation, Senior Cardiology Clinical Pharmacist, Therapeutic Affairs Deputyship, Ministry of Health, KSA
Scientific Committee Chair

Hajer Al-Mudaiheem
Board Member, Saudi Society of Clinical Pharmacy (SSCP), KSA
Strategic Partner
AN INITIATIVE BY